Acer Therapeutics Submits NDA for Edsivo (celiprolol) for the Treatment of Vascular Ehlers-Danlos syndrome (vEDS)

NEWTON, MA– October 29, 2018– Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news